Aim Blauvelt et al. aimed to compare the long‐term efficacy and safety of dupilumab with
medium‐potency topical corticosteroids (TCS) vs. placebo with TCS in adults with moderate …

This guideline is an update from August 2020 the S2k‐guideline “Atopic dermatitis”
published in 2015. The reason for updating this chapter of the guideline were the current …

Atopic dermatitis (AD) is the most common inflammatory skin disease. Recent research
findings have provided an insight into the complex pathogenic mechanisms involved in this …

Atopic dermatitis (AD) is a chronic, systemic disease that has a multifactorial etiology, where
immune system disorders and epidermal barrier dysfunction are added to the influence of …

Background: Atopic dermatitis (AD) can be debilitating and often requires the use of
combination topical and systemic therapy to achieve adequate disease control. Methods: A …

Comment www. thelancet. com Vol 387 January 2, 2016 5 by 73· 7% in the highest dosage
group (300 mg once a week), 68· 2% in the second highest dosage group (300 mg every 2 …

Background Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks
signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous …